BioMimetic Therapeutics, Inc. (BMTI) Reports Q3 Loss of $0.25
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Price: $9.49 --0%
Financial Fact:
Depreciation and capital lease amortization: 233.35K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Depreciation and capital lease amortization: 233.35K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) reported Q3 EPS of ($0.25), $0.06 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $428 million versus the consensus estimate of $350 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
